cyclooctatin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cyclooctatin : A diterpenoid characterized by a 5-8-5 dodecahydrodicyclopenta[a,d]cyclooctene fused-ring system, with a single double bond and one isopropyl, two hydroxy, one hydroxymethyl and two methyl substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 132282047 |
| CHEMBL ID | 4289906 |
| CHEBI ID | 78370 |
| MeSH ID | M0211478 |
| Synonym |
|---|
| cyclooctatin |
| CHEBI:78370 |
| (1r,3r,3as,4s,6z,7r,9ar,10ar)-1-(hydroxymethyl)-4,9a-dimethyl-7-(propan-2-yl)-1,2,3,3a,4,5,7,8,9,9a,10,10a-dodecahydrodicyclopenta[a,d][8]annulene-3,4-diol |
| (1r,3r,3as,4s,6z,7r,9ar,10ar)-1-(hydroxymethyl)-7-isopropyl-4,9a-dimethyl-1,2,3,3a,4,5,7,8,9,9a,10,10a-dodecahydrodicyclopenta[a,d][8]annulene-3,4-diol |
| (1r,3r,3as,4s,6z,7r,9ar,10ar)-1-(hydroxymethyl)-7-isopropyl-4,9a-dimethyl-1,2,3,3a,4,5,7,8,9,9a,10,10a-dodecahydrodicyclopenta[a,d]cyclooctene-3,4-diol |
| (1r,3r,3as,4s,6z,7r,9ar,10ar)-1-(hydroxymethyl)-4,9a-dimethyl-7-(propan-2-yl)-1,2,3,3a,4,5,7,8,9,9a,10,10a-dodecahydrodicyclopenta[a,d]cyclooctene-3,4-diol |
| CHEMBL4289906 |
| Role | Description |
|---|---|
| EC 3.1.1.5 (lysophospholipase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of the enzyme lysophospholipase (EC 3.1.1.5), which catalyses the release of fatty acids from lysophospholipids. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| carbotricyclic compound | A carbopolyclic compound comprising of three carbocyclic rings. |
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1423929 | Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423923 | Cytotoxicity against human HeLa cells assessed as inhibition of growth at 200 uM incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1877680 | Induction of autophagy in human HeLa cells stably expressing EGFP-LC3 assessed as increase in EGFP-LC3 puncta formation at 25 uM incubated for 24 hrs by fluorescence microscopic analysis | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Streptooctatins A and B, fusicoccane-type diterpenoids with autophagic activity from Streptomyces sp. KCB17JA11. |
| AID1423925 | Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423920 | Cytotoxicity against human BGC823 cells assessed as inhibition of growth at 200 uM incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423928 | Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423921 | Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth at 200 uM incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423922 | Cytotoxicity against human HCT116 cells assessed as inhibition of growth at 200 uM incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1423924 | Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth at 200 uM incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1877678 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability up to 100 uM | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Streptooctatins A and B, fusicoccane-type diterpenoids with autophagic activity from Streptomyces sp. KCB17JA11. |
| AID1423927 | Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| AID1877677 | Induction of autophagy in human HeLa cells assessed as increase in LC3-II protein expression level at 10 to 50 uM uM incubated for 24 hrs by western blot analysis | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Streptooctatins A and B, fusicoccane-type diterpenoids with autophagic activity from Streptomyces sp. KCB17JA11. |
| AID1423926 | Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||